|
|
ACRO產品矩陣賦能哮喘藥物開發
哮喘是一種異質性慢性炎症疾病，其核心是氣道免疫失衡。《柳葉刀》資料顯示，全球約3.39億人受哮喘困擾，但傳統治療（吸入激素、β受體激動劑）僅能控制症狀，無法阻斷疾病進展。隨著Th2型（2型炎症）與非Th2型（非2型炎症）分類體系的建立，哮喘治療進入“分型而治”的新紀元。Th2型炎症覆蓋約50%-70%患者，以嗜酸粒細胞、 TSLP、IgE、IL-4/IL-13和IL-5為核心驅動，靶向藥物已進入收穫期；非Th2型炎症占30%-50%，涉及中性粒細胞、IL-6、IL-17等機制，或為突破治療瓶頸的新方向。
|
|
doi: 10.1016/S0140-6736(17)33311-1
哮喘免疫學病理機制
|
|
|
IL-7Rα & TSLPR抑制劑篩選試劑盒
(Cat. No. EP-129)
|
|
Serial dilutions of Anti-TSLP Neutralizing antibody (Catalog # EP129-C03) (1:1 serial dilution, from 8 μg/mL to 0.0156 μg/mL (55.317-0.108 nM)) was added into IL-7 R alpha & TSLP R: TSLP-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
點擊申請Protocol
|
|
|
|
IL-4Rα抑制劑篩選試劑盒
(Cat. No. EP-132)
|
|
Serial dilutions of Human IL-4(Catalog # EP132-C03) (1:1 serial dilution, from 5 μg/mL to 0.01 μg/mL (295.86-0.58 nM)) was added into IL-4 R alpha: IL-4-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
點擊申請Protocol
|
|
|
|
|
Cynomolgus Fc epsilon RI alpha, His Tag (Cat. No. FCA-C52H9) immobilized on CM5 Chip can bind Human IgE Fc, His Tag (Cat. No. IGE-H52H9) with an affinity constant of 0.226 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
點擊申請Protocol
|
|
|
|
Loaded Biotinylated Human IL17A, His, Avitag (Cat. No. ILA-H82Q1) on SA Biosensor, can bind Human IL-17 RA, His Tag (Cat. No. ILA-H5222) with an affinity constant of 18.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
點擊申請Protocol
|
|
|
|
|
|
